BioVie Slashes Offering to $25M, Lifts Price to $1.56 in S-1 Amendment
BIVI sits 66% above its 52-week low of $0.82.
Summary
BioVie reduced its best-efforts offering to $25 million and raised the assumed price to $1.56 per share, a material change from the prior $75 million plan.
Key Events · Financing and Capital Events · BIVI
-
Offering Size Cut to $25M
Amendment No. 3 reduces the best-efforts offering from up to $75 million to $25 million, with 16,025,641 shares and accompanying warrants.
-
Assumed Price Raised to $1.56
The assumed combined public offering price per share and warrant increased from $1.33 to $1.56, the last reported Nasdaq price on August 13, 2026.
-
Net Proceeds Estimate Lowered
Estimated net proceeds drop to approximately $22.7 million, down from prior estimates, after placement agent fees and expenses.
-
Warrant Terms Set
Common Warrants have an exercise price of $1.95 (125% of $1.56) and expire five years from issuance; Pre-funded Warrants have a $0.0001 exercise price.
Analysis · BIVI · Life Sciences
The latest S-1 amendment from BioVie cuts the best-efforts offering from up to $75 million to $25 million while raising the assumed price from $1.33 to $1.56 per share. With only $9 million in cash and a going concern warning, the company may find this smaller raise insufficient to fully fund operations. The higher price reduces dilution but also signals weaker demand or a strategic pivot to a more achievable financing.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40.1% of the 1118 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIVI was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.82 to $3.79. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.